RT Journal Article SR Electronic T1 NSAIDs for analgesia in the era of COVID-19 JF Regional Anesthesia & Pain Medicine JO Reg Anesth Pain Med FD BMJ Publishing Group Ltd SP 677 OP 678 DO 10.1136/rapm-2020-101584 VO 45 IS 9 A1 Daniel L Herzberg A1 Harry P Sukumaran A1 Eugene Viscusi YR 2020 UL http://rapm.bmj.com/content/45/9/677.abstract AB Globally, non-steroidal anti-inflammatory drugs (NSAIDs) are highly used to treat pain. With the rise of the COVID-19 pandemic, the safety of NSAIDs use has been called into question. These concerns are worthy of review. At present, there is no compelling data showing that NSAIDs worsen the severity of COVID-19 symptoms or increase one’s likelihood of contracting the illness. For patients in pain and without symptoms that could potentially be attributed to COVID-19 (cough, fevers/chills, lethargy, myalgias, anosmia and so on), NSAIDs should continue to remain a viable option to provide analgesia to patients in need.